Clinical Trials Browser

Terminated × Multiple Myeloma × Alemtuzumab × Clear all

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT00698685 2017-03-31

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

GenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Carcinoma, Renal Cell, Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00579111 2016-05-04

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Phase 1/2 Terminated

4 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Paraproteinemias, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)